The use of first-generation EGFR TKIs in combination with immune checkpoint inhibitors (ICIs) has been investigated in three phase 1 clinical trials in patients with EGFR-mutant NSCLC [63,64,65]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.